应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02269 药明生物
交易中 09-18 15:19:24
50.450
+0.350
+0.70%
最高
51.900
最低
50.150
成交量
2,917万
今开
50.350
昨收
50.100
日振幅
3.49%
总市值
2,097亿
流通市值
2,097亿
总股本
41.56亿
成交额
14.87亿
换手率
0.70%
流通股本
41.56亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读｜药明生物盘中上涨3.09%，CXO板块持续走强叠加多重利好共振
行情直击 · 09:51
异动解读｜药明生物盘中上涨3.09%，CXO板块持续走强叠加多重利好共振
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
金吾财讯 · 09:46
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
生物医药概念走强 再鼎医药（09688）涨超4% 十部门出台医药工业十五五规划
金吾财讯 · 09:45
生物医药概念走强 再鼎医药（09688）涨超4% 十部门出台医药工业十五五规划
药明生物：陈智胜减持，好仓比例降至1.47%
港股披露 · 09-17 17:41
药明生物：陈智胜减持，好仓比例降至1.47%
【千亿药企龙头深度拆解】药明系：上市主体的资本与产业实验
港股解码 · 09-17 16:05
【千亿药企龙头深度拆解】药明系：上市主体的资本与产业实验
创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来
金吾财讯 · 09-16 10:20
创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来
异动解读｜药明生物盘中上涨3.21%，CXO板块延续中报行情集体走强
行情直击 · 09-16 09:49
异动解读｜药明生物盘中上涨3.21%，CXO板块延续中报行情集体走强
港股异动 | CRO概念股涨幅居前、凯莱英大涨12%，中报持续验证行业高景气，多家公司上调业绩指引
智通财经 · 09-14
港股异动 | CRO概念股涨幅居前、凯莱英大涨12%，中报持续验证行业高景气，多家公司上调业绩指引
港股早盘低开高走 恒生指数半日上涨0.35% 药明生物（02269）涨4.81%
金吾财讯 · 09-14
港股早盘低开高走 恒生指数半日上涨0.35% 药明生物（02269）涨4.81%
异动解读｜药明生物盘中上涨3.06%，CXO板块集体走强带动反弹
行情直击 · 09-14
异动解读｜药明生物盘中上涨3.06%，CXO板块集体走强带动反弹
医药板块表现强势 凯莱英（06821）涨超5% 机构制AI制药商业化风口初步显现
金吾财讯 · 09-14
医药板块表现强势 凯莱英（06821）涨超5% 机构制AI制药商业化风口初步显现
港股异动 | CRO概念股涨幅居前 中报持续验证行业高景气 多家公司上调业绩指引
智通财经 · 09-14
港股异动 | CRO概念股涨幅居前 中报持续验证行业高景气 多家公司上调业绩指引
异动解读｜药明生物盘中下跌3.07%，报47.38港元
行情直击 · 09-10
异动解读｜药明生物盘中下跌3.07%，报47.38港元
【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段
金吾财讯 · 09-10
【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段
药明生物：9月9日发行120万股并多次回购股份累计约3,982.45万股
公告速递 · 09-09
药明生物：9月9日发行120万股并多次回购股份累计约3,982.45万股
药明生物(02269.HK)因期权获行使而发行120万股
智通财经 · 09-09
药明生物(02269.HK)因期权获行使而发行120万股
创胜集团医药-B授予药明生物Hicb平台及Excelpro细胞培养基非独家许可
美股速递 · 09-09
创胜集团医药-B授予药明生物Hicb平台及Excelpro细胞培养基非独家许可
商务部新增84个全国重点外资项目
同花顺 · 09-08
商务部新增84个全国重点外资项目
药明生物自5月27日至7月7日回购3,982.45万股，涉资约12.72亿港元，并于9月7日发行180.41万股
公告速递 · 09-07
药明生物自5月27日至7月7日回购3,982.45万股，涉资约12.72亿港元，并于9月7日发行180.41万股
药明生物9月4日增发320万股并累计回购3982.45万股，耗资约12.72亿港元
公告速递 · 09-04
药明生物9月4日增发320万股并累计回购3982.45万股，耗资约12.72亿港元
加载更多
公司概况
公司名称：
药明生物
所属市场：
SEHK
上市日期：
--
主营业务：
药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":50.45,"timestamp":1789715963849,"preClose":50.1,"halted":0,"volume":29167666,"delay":0,"changeRate":0.006986027944111805,"floatShares":4156000000,"shares":4156000000,"eps":1.3600202740188119,"marketStatus":"交易中","change":0.35,"latestTime":"09-18 15:19:24","open":50.35,"high":51.9,"low":50.15,"amount":1487478463,"amplitude":0.03493,"askPrice":50.45,"askSize":81000,"bidPrice":50.4,"bidSize":58000,"shortable":3,"etf":0,"ttmEps":1.3878830397417492,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789719000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":50.1,"openAndCloseTimeList":[[1789695000000,1789704000000],[1789707600000,1789718400000]],"volumeRatio":1.114728,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5164,"impliedVolPercentile":0.5755},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"1166709095","title":"异动解读｜药明生物盘中上涨3.09%，CXO板块持续走强叠加多重利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1166709095","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166709095?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:51","pubTimestamp":1789696260,"startTime":"0","endTime":"0","summary":"9月18日，药明生物盘中上涨3.09%，报51.6港元/股，成交额3.71亿港元。消息面上，CXO板块延续强势，全球医药研发外包率突破50%，行业内外需共振向上。公司上半年收益117.87亿元，同比增长18.4%，经调整归母净利同比增长38.4%，全年收入增长指引上调至15%-18%，未完成订单约55亿美元，同比增约30%。同板块中，金斯瑞生物科技涨6.39%，昭衍新药涨9.71%，板块联动效应显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中上涨，CXO板块利好共振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0039217434.USD","LU2242644610.SGD","LU0128522744.USD","03347","LU1688375341.USD","LU3063872942.SGD","IE00B0JY6N72.USD","02269","BK0216","LU0469268626.HKD","LU0051755006.USD","KURE","02359","BK1610","BK1588","LU1880383366.USD","BK1161","LU0359202008.SGD","LU0856984785.SGD","06160","LU0561508036.HKD","LU0052750758.USD","LU0516423174.USD","LU0634319403.HKD","06821","LU0828237510.HKD","01873","01548","06127","LU0228659784.USD","LU1719994722.HKD","603127","LU0320764243.SGD","CXO","WX","LU0348735423.USD","SG9999002562.SGD","LU0588546209.SGD","LU0348825331.USD","LU0348827113.USD","LU0456846285.SGD","LU1251922891.USD","LU0029874061.USD","LU1242518931.SGD","LU0181495838.USD","LU0320764599.SGD","LU0029874905.USD","BK1521","LU1242518857.USD","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668813919","title":"生物医药概念走强 再鼎医药（09688）涨超4% 十部门出台医药工业十五五规划","url":"https://stock-news.laohu8.com/highlight/detail?id=2668813919","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668813919?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:45","pubTimestamp":1789695942,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药概念走强，截至发稿，金斯瑞生物科技 涨4.78%，再鼎医药涨4.57%，君实生物涨3.32%，泰格医药涨1.93%，药明生物涨1.70%。消息面上，工业和信息化部、国家发展改革委等十部门联合发布《医药工业发展“十五五”规划》。《规划》提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991931","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0417516902.SGD","161726","BK4531","LU0029874061.USD","LU0572944931.SGD","LU0634319403.HKD","LU3063872942.SGD","LU0348825331.USD","LU0516422366.SGD","LU0043850808.USD","LU1688375341.USD","01548","SG9999002463.SGD","LU2488822045.USD","LU0128526141.USD","LU0417516738.SGD","LU0561508036.HKD","LU0181495838.USD","XBI","02269","LU0348735423.USD","HK0000320264.USD","LU0516423174.USD","BK1521","LU0320764243.SGD","LU0979878070.USD","09688","BK1161","LU0856984785.SGD","LU1242518931.SGD","BK4588","01877","BK1610","LU0326950275.SGD","LU0588546209.SGD","LU0516423091.SGD","KURE","LU0320764599.SGD","LU0128522744.USD","03347","BK1141","ZLAB","HK0000306685.HKD","LU0456846285.SGD","BK4139","LU0140636845.USD","LU0348827113.USD","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188559283","title":"药明生物：陈智胜减持，好仓比例降至1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188559283","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188559283?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:41","pubTimestamp":1789638099,"startTime":"0","endTime":"0","summary":"陈智胜于2026年9月11日在联交所场内以每股均价49.1359港元卖出药明生物股份120.00万股，涉资约5896.31万港元，属场内主动交易，即在二级市场直接买卖股份。该笔卖出源于陈智胜依据公司首次公开发售前购股权计划行使购股权后所得股份的出售，以满足税务等负债。陈智胜此次减持前持有药明生物好仓6218.11万股，占比1.5%；减持后持股量为6098.11万股，好仓比例降至1.47%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668993356","title":"【千亿药企龙头深度拆解】药明系：上市主体的资本与产业实验","url":"https://stock-news.laohu8.com/highlight/detail?id=2668993356","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668993356?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:05","pubTimestamp":1789632300,"startTime":"0","endTime":"0","summary":"李革联合私募基金，以约33亿美元将药明康德从纽交所私有化退市。退市不是终点，而是重新切割业务、分批资本化的起点。药明生物是从药明康德大分子板块独立出来的公司，主业是大分子生物药CRDMO，包括抗体、双抗、融合蛋白、疫苗等生物药的研发与生产。药明合联的价值，正是依托药明生物的大分子平台、药明康德/合全药业的小分子平台，完成偶联、制剂与规模化生产，实现整套链条协同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514222&idx=1&sn=a5888f47603d14bfee478c846e35b8f0&chksm=f321e62ca04295728bbd6dcb9b1f75e4de3b57897423b59c2fa696ad13c6ef57c2cb3924a020&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0463099449.HKD","BK1583","HK0000165453.HKD","LU0149534421.HKD","02126","LU0039217434.USD","BK1191","LU0348766576.USD","LU1023057109.AUD","LU0516422440.USD","LU2045819591.USD","KURE","LU2125910500.SGD","LU2242644610.SGD","LU0417516738.SGD","LU0856984785.SGD","LU0128526141.USD","LU1720050803.USD","LU0327786744.USD","LU0244354667.USD","BK1141","02268","LU1880383366.USD","LU0359202008.SGD","01276","IE00B0JY6N72.USD","03347","LU0348827113.USD","LU0326950275.SGD","LU0823426480.USD","02269","LU0819121731.USD","LU0469268626.HKD","LU1188198961.HKD","LU0708995583.HKD","LU1046422090.SGD","LU2097828631.EUR","LU0029874061.USD","LU0588546209.SGD","LU0540923850.HKD","LU2039709279.SGD","LU0502904849.HKD","LU0128522744.USD","LU2097828557.USD","LU1794554557.SGD","LU0320764243.SGD","01875","01801","03759","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617679","title":"创新药概念局部走强 恒瑞医药（01276）涨2.74% 机构料企业扭亏节点到来","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617679","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617679?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:20","pubTimestamp":1789525259,"startTime":"0","endTime":"0","summary":"消息面上，国金证券表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。诚通证券表示，2025年为创新药海外授权BD大年，2026H1我国创新药海外授权BD交易继续大幅增长，总交易金额已接近1000亿美元，国产创新药已从偶发性出海转变为系统性趋势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991724","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","600276","LU0456846285.SGD","09688","01177","LU0417516902.SGD","LU2039709279.SGD","LU2148510915.USD","BK0060","159992","LU0359201612.USD","LU0516423174.USD","LU1023057109.AUD","BK1574","IBBQ","LU2097828805.USD","LU0128526141.USD","01276","LNGR","LU0348825331.USD","BK0239","LU1580142542.USD","01477","LU1328615791.USD","KURE","LU0043850808.USD","LU0348827113.USD","06978","LU0561508036.HKD","LU0140636845.USD","LU0327786744.USD","LU0588546209.SGD","BK1515","MEDX","02269","LU2097828557.USD","02637","LU0405327148.USD","LU1655091616.SGD","IE00BZ08YS42.EUR","LU1820825898.SGD","LU1146622755.USD","LU2488822045.USD","LU0307460666.USD","LU2580892789.USD","BK0188","IE00B0JY6N72.USD","LU1255011170.USD","BK0183","LU0516422952.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119281451","title":"异动解读｜药明生物盘中上涨3.21%，CXO板块延续中报行情集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1119281451","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119281451?lang=zh_cn&edition=full","pubTime":"2026-09-16 09:49","pubTimestamp":1789523358,"startTime":"0","endTime":"0","summary":"9月16日，药明生物盘中上涨3.21%，报50.85港元/股，成交额2.41亿港元。消息面上，CXO板块近期持续走强，多家公司中报业绩验证行业高景气。同板块中，康龙化成涨3.88%，金斯瑞生物科技涨3.34%，药明康德涨2.63%，板块联动效应显著。此外，AI制药商业化风口初步显现，头部CXO企业主动融合AI能力，行业中长期成长空间进一步打开。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中走强，CXO板块中报行情延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667763172","title":"港股异动 | CRO概念股涨幅居前、凯莱英大涨12%，中报持续验证行业高景气，多家公司上调业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667763172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667763172?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:34","pubTimestamp":1789364090,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，凯莱英涨5.89%，报142.1港元；康龙化成涨4.72%，报28.84港元；泰格医药涨4.64%，报43.32港元；药明生物涨2.30%，报48.08港元。消息面上，国内外CXO公司中报业绩持续验证行业高景气。国内药明康德发布中报，业绩大幅超市场预期，同时大幅上调全年业绩指引。该行表示，看好药明系、康龙化成、凯莱英、泰格医药及金斯瑞。","market":"fut","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495468.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | CRO概念股涨幅居前，中报持续验证行业高景气，多家公司上调业绩指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0327786744.USD","LU0456827905.SGD","BK1610","LU0359202008.SGD","LU1720050803.USD","LU3063872942.SGD","LU0359201612.USD","BK1521","LU0588546209.SGD","BK1583","LU2039709279.SGD","LU0029874061.USD","LU0181495838.USD","LU0348827113.USD","LU0561508036.HKD","LU0856984785.SGD","SG9999002463.SGD","LU0348825331.USD","LU1880383366.USD","LU0819121731.USD","LU0823426308.USD","BK1191","KURE","LU0051755006.USD","LU0320764599.SGD","LU0348735423.USD","LU0516423091.SGD","06821","VXUS","LU0572944931.SGD","LU0140636845.USD","KCAI","LU0326950275.SGD","LU0417516738.SGD","BK4588","LU0516423174.USD","LU0307460666.USD","LU0456846285.SGD","LU1688375341.USD","LU0039217434.USD","LU0128526141.USD","LU0823426480.USD","03347","LU0516422952.EUR","BK1589","LU0979878070.USD","02269","03759","LU0516422366.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667378766","title":"港股早盘低开高走 恒生指数半日上涨0.35% 药明生物（02269）涨4.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667378766","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667378766?lang=zh_cn&edition=full","pubTime":"2026-09-14 12:18","pubTimestamp":1789359482,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘低开高走，截至午间收盘，恒生指数上涨0.35%；国企指数上涨0.4%，恒生科技指数上涨0.17%。医药概念板块表现强势，凯莱英涨10.88%，康龙化成涨5.15%，泰格医药涨7%，药明康德涨4.61%，药明生物涨4.81%。个股方面，联想集团股价扬升，半日涨4.6%。在中国x86服务器市场，第二季度，联想的x86服务器营收同比增长9.0%，以10.5%的市场份额排名第四。长风药业股价冲高回落，半日涨1.16%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991494","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048580855.USD","02652","LU0856984785.SGD","LU1880383366.USD","LU0370786039.SGD","LU0979878070.USD","LU1242518857.USD","LU0039217434.USD","LU0708995583.HKD","LU0456827905.SGD","BK1191","BK1589","03037","BK1576","LU1808992512.USD","LU0049112450.USD","LU0348735423.USD","WXXWY","07300","LU1785774172.SGD","09115","LU1366334651.USD","BK1141","BK1193","LU0561508036.HKD","SG9999002463.SGD","HHImain","00992","80992","MCHmain","LU1366334578.USD","LU1794554557.SGD","LU0543330483.HKD","BK1610","LU0320764599.SGD","LU1267930227.SGD","07200","LU1235295612.USD","IE0032431581.USD","LU0348825331.USD","LU0516423091.SGD","LU0326950275.SGD","LU0359201612.USD","LU0572939691.SGD","LU0043850808.USD","07500","LU1688375341.USD","513600","HK0000306685.HKD","BK1607","LU0359202008.SGD","LU0417516738.SGD","HK0000320223.HKD","LU0823426480.USD","LU0672654166.SGD","BK1521","BK1526","LU0791591158.USD","LU0862451837.USD","LU0029875118.USD","LU0128526141.USD","LU0516422952.EUR","LU0307460666.USD","LU2242644610.SGD","LU0572944931.SGD","HK0000306701.USD","LU0456846285.SGD","LU0862451753.SGD","LU0890818403.SGD","LU0972618739.USD","SG9999002562.SGD","LU0516422440.USD","LU0320764755.SGD","IE00B0JY6N72.USD","LU0310800965.SGD","KURE","82800","LU3063872942.SGD","LU0052750758.USD","HSI","IE0003895053.USD","LU0327786744.USD","IE0034224299.USD","LU1242518931.SGD","LU0128522157.USD","LU2039709279.SGD","LU0140636845.USD","LU0819121731.USD","LU0051755006.USD","03115","LU0348827113.USD","LU0052756011.USD","LU0791590937.USD","HK0000320264.USD","LU0128525689.USD","LU1720050803.USD","83115","LU0181495838.USD","02833","LU0572940350.SGD","LU0516423174.USD","02269","02800","HSTECH","LU1046422090.SGD","LU0417516902.SGD","LU0264606111.USD","LU0588546209.SGD","LU0029874061.USD","LU0516422366.SGD","TCHI","03419","LNVGY","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198560754","title":"异动解读｜药明生物盘中上涨3.06%，CXO板块集体走强带动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1198560754","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198560754?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:27","pubTimestamp":1789352861,"startTime":"0","endTime":"0","summary":"9月14日，药明生物盘中上涨3.06%，报48.44港元/股，成交额3.45亿港元。同日生命科学工具和服务板块集体走强，康龙化成涨5.74%，药明康德涨3.23%，金斯瑞生物科技涨2.35%。消息面上，近期CXO及创新药板块迎来估值修复行情，多家券商确认板块底部特征，\"药明系\"企业此前推出合计最高约55亿元回购计划对股价形成提振。公司层面，上半年收益117.87亿元，同比增长18.4%，经调整归母净利同比增长38.4%，全年业绩指引上调；未完成订单约55亿美元，同比增长约30%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中走强，CXO板块集体反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667083631","title":"医药板块表现强势 凯莱英（06821）涨超5% 机构制AI制药商业化风口初步显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2667083631","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667083631?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:26","pubTimestamp":1789352818,"startTime":"0","endTime":"0","summary":"消息面上，招商证券指出，自2024年以来，AI制药发展速度明显加快，投资规模和项目数量显著增长。跨国药企开始大规模搭建自有AI平台能力，合作模式由单点项目合作转向管线与平台层面深度合作。AI科技巨头入局药物研发领域，依托通用大模型推出面向药物研发的专用AI模型。AI Biotech的合作机会与交易规模持续扩容，即便尚未拥有成熟商业化管线，也获得传统药企青睐。AI制药行业已完成概念验证，正式迈入临床验证阶段，商业化风口初步显现。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991473","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU1880383366.USD","BK1583","LU1242518931.SGD","02269","BK1610","AGIX","LU0516422440.USD","BK0239","VTHR","LU0417516902.SGD","BK1141","159938","LU0979878070.USD","KURE","AIPO","BK1515","CHAT","LU0348766576.USD","LU0417516738.SGD","ARTY","LU0819121731.USD","LU0043850808.USD","LU0516423174.USD","LU1720050803.USD","LU1328615791.USD","LU2125910500.SGD","BK1191","LU0516422366.SGD","QTOC","LU1242518857.USD","LU0359201612.USD","03347","LU0588546209.SGD","03759","LU0823426480.USD","SG9999002463.SGD","LU0128526141.USD","02359","IE00B0JY6N72.USD","06821","LU1688375341.USD","01477","09939","LU0326950275.SGD","002821","LU0307460666.USD","LU2242644610.SGD","LU1046422090.SGD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667778631","title":"港股异动 | CRO概念股涨幅居前 中报持续验证行业高景气 多家公司上调业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2667778631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667778631?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:23","pubTimestamp":1789352605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348825331.USD","06821","LU1688375341.USD","LU0516422366.SGD","03759","LU0588546209.SGD","SG9999002562.SGD","BK1589","LU1880383366.USD","KURE","LU1720050803.USD","BK1521","LU0348735423.USD","LU0359202008.SGD","LU0516423174.USD","LU0417516738.SGD","LU0348827113.USD","LU0359201612.USD","LU0456846285.SGD","LU0516422952.EUR","LU0819121731.USD","SG9999002463.SGD","LU0708995583.HKD","IE00B0JY6N72.USD","LU0320764599.SGD","LU1794554557.SGD","LU0456827905.SGD","LU0029874061.USD","02269","LU0307460666.USD","BK1141","BK1583","LU0181495838.USD","BK1191","LU2039709279.SGD","LU0823426480.USD","BK1610","LU0516423091.SGD","LU0572944931.SGD","LU0979878070.USD","LU0052750758.USD","03347","LU0516422440.USD","LU1242518857.USD","LU0856984785.SGD","BK1576","LU0043850808.USD","LU0561508036.HKD","LU0128526141.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171381892","title":"异动解读｜药明生物盘中下跌3.07%，报47.38港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171381892","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171381892?lang=zh_cn&edition=full","pubTime":"2026-09-10 11:01","pubTimestamp":1789009288,"startTime":"0","endTime":"0","summary":"9月10日，药明生物盘中下跌3.07%，报47.38港元/股，成交额5.16亿港元。药明生物所在的生命科学工具和服务行业整体走弱，个股中，英矽智能跌0.75%，金斯瑞生物科技跌3.21%，药明康德跌0.78%，药明合联跌1.75%，晶泰控股跌0.55%。药明生物是一家主要从事向生物制剂行业客户提供生物发现、开发及生产端到端解决方案及服务的投资控股公司，业务涵盖生物药及XDC两大分部，在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","KCE","01801","01177","LU0516422952.EUR","LU2039709279.SGD","LU1255011170.USD","LU1820825898.SGD","KURE","LU1580142542.USD","LU1961090484.USD","LU2580892862.HKD","01093","SG9999004220.SGD","02142","LU1997245177.USD","09688","LU0979878070.USD","LU1655091616.SGD","LU0181495838.USD","LU2148510915.USD","LU1064130708.USD","BK1161","01877","LU1794554557.SGD","LU0561508036.HKD","BK1141","09995","LU1226287875.USD","LU1720050803.USD","09926","06160","LU1813983027.USD","LU0819121731.USD","02616","LU0417516738.SGD","600030","LU0572944931.SGD","LU0348825331.USD","LU1969619763.USD","LU0348783233.USD","06030","02269","IE00B543WZ88.USD","LU0463099449.HKD","LU1226287792.SGD","BK0028","06185","LU1880383366.USD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165341452","title":"药明生物：9月9日发行120万股并多次回购股份累计约3,982.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1165341452","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165341452?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:42","pubTimestamp":1788961372,"startTime":"0","endTime":"0","summary":"2026年9月9日，药明生物发布翌日披露报表，宣布于当日根据2016年1月5日采纳并于2016年8月10日修订的首次公开发售前购股权计划，因董事行使期权，按每股2.64港元发行120万股普通股，占截至2026年9月7日公司已发行股份约0.02888%。本次发行后，公司已发行股本增至4,155,933,877股。此外，公司自2026年5月27日至7月7日期间，于香港联交所场内多次回购合计3,982.45万股，回购股数占当时已发行股本的日均比重介乎0.03486%至0.15734%，每股回购价格介乎每股29.46港元至36.75港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物：9月9日发行120万股并多次回购股份累计约3,982.45万股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666653665","title":"药明生物(02269.HK)因期权获行使而发行120万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666653665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666653665?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:40","pubTimestamp":1788961206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0128526141.USD","LU0572944931.SGD","LU0417516902.SGD","LU0348825331.USD","LU0456846285.SGD","LU0320764599.SGD","LU0856984785.SGD","LU0181495838.USD","LU0516422366.SGD","LU0307460666.USD","02269","LU1688375341.USD","LU0456827905.SGD","LU1242518857.USD","BK1576","LU0819121731.USD","BK1141","LU0043850808.USD","KURE","LU0588546209.SGD","LU0708995583.HKD","LU0359202008.SGD","LU0516422440.USD","LU1242518931.SGD","LU0979878070.USD","LU2039709279.SGD","LU0359201612.USD","LU1880383366.USD","LU0039217434.USD","LU0326950275.SGD","LU0029874061.USD","LU3063872942.SGD","BK1521","LU0823426480.USD","LU0140636845.USD","LU1720050803.USD","LU1794554557.SGD","LU0051755006.USD","SG9999002463.SGD","BK1589","LU0516423174.USD","IE00B0JY6N72.USD","BK1610","LU0516422952.EUR","LU0417516738.SGD","LU0348735423.USD","LU0823426308.USD","LU0516423091.SGD","LU0327786744.USD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118201250","title":"创胜集团医药-B授予药明生物Hicb平台及Excelpro细胞培养基非独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1118201250","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118201250?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:02","pubTimestamp":1788955330,"startTime":"0","endTime":"0","summary":"创胜集团医药-B（TRANSCENTA-B）宣布，已向药明生物（WUXI BIO）授予其Hicb平台及Excelpro细胞培养基的非独家许可。\n这一举措标志着两家生物医药企业之间的深度合作。通过该协议，药明生物将获得使用创胜集团先进的Hicb抗体发现平台和高效的Excelpro细胞培养基技术的权限。\n值得注意的是，非独家授权的形式允许创胜集团未来继续向其他合作伙伴提供相同技术，而药明生物则能借此增强其研发和生产能力。业界观察人士认为，此类技术共享有助于加速生物制剂的开发进程，并可能对行业竞争格局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0051755006.USD","LU1688375341.USD","LU0516422366.SGD","LU0326950275.SGD","LU0417516902.SGD","LU0588546209.SGD","SG9999002562.SGD","BK1589","LU1880383366.USD","LU0039217434.USD","KURE","LU1720050803.USD","BK1521","BK1161","LU0348735423.USD","LU0359202008.SGD","LU0516423174.USD","LU0823426308.USD","LU0417516738.SGD","LU0516422952.EUR","LU0359201612.USD","LU0456846285.SGD","LU0819121731.USD","SG9999002463.SGD","LU0708995583.HKD","06628","IE00B0JY6N72.USD","LU0320764599.SGD","LU0327786744.USD","LU0029874061.USD","02269","LU0456827905.SGD","LU1242518931.SGD","LU1794554557.SGD","LU0307460666.USD","BK1141","LU0181495838.USD","LU3063872942.SGD","LU2039709279.SGD","LU0823426480.USD","BK1610","LU0516423091.SGD","LU0572944931.SGD","LU0979878070.USD","LU0052750758.USD","LU0516422440.USD","LU1242518857.USD","LU0856984785.SGD","BK1576","LU0043850808.USD","LU0128526141.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341019","title":"商务部新增84个全国重点外资项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341019","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665341019?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:05","pubTimestamp":1788840300,"startTime":"0","endTime":"0","summary":"【大河财立方记者程帅星厦门报道】9月8日，大河财立方记者在第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)上获悉，商务部近日新增84个全国重点外资项目，其中包括6个外资标志性项 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679692496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU0882574055.USD","LU2168564222.USD","LU2023250504.SGD","LU2237443622.USD","LU2471134952.CNY","LU0689472784.USD","LU0823413660.USD","BK4568","IE00BFSS7M15.SGD","IE00BJJMRZ35.SGD","LU0683600562.USD","LU1057294990.SGD","LU0572944931.SGD","LU1720051017.SGD","LU2112291526.USD","LU1804176565.USD","LU3063872942.SGD","LU0114720955.EUR","LU0061475181.USD","LU0823413587.USD","LU2237438978.USD","LU0181495838.USD","LU2756315664.SGD","LU1323610961.USD","LU1983299246.USD","LU0516422440.USD","LU0316494557.USD","IHE","LU2360106947.USD","LU2023250330.USD","LU0823397103.USD","LU1956131251.USD","BK1610","SKHA","LU2552382058.USD","ILDR","SGXZ51526630.SGD","IE00B4JS1V06.HKD","LU0133085943.USD","LU1093756168.USD","LU2213496289.HKD","SG9999001176.SGD","LU0385154629.USD","SG9999014914.USD","SG9999014880.SGD","02269","LU1989771016.USD","LU0128526141.USD","LU0823397285.USD","LLY","BK0188","LU0320765059.SGD","TRUH","BK1576","SK","LU2237443465.HKD","BK4585","IE00BN29S564.USD","PJP","LU0097036916.USD","LU0128525929.USD","BK0196","SKUU","LLII","LU0094547139.USD","LU2361044865.SGD","LU2168564495.EUR","IE00BFTCPJ56.SGD","SKHX","LU2063271972.USD","SG9999014906.USD","LU0174119429.USD","LU0856984785.SGD","LU0256863811.USD","GDOC","LU0140636845.USD","SKHY","LU0588546209.SGD","IE00BK4W5M84.HKD","LU2552382132.HKD","LU2039709279.SGD","BK4141","LU0310800379.SGD","SG9999015978.USD","LU0516422366.SGD","LU1691799644.USD","LU0432979614.USD","BK4096","LU0417516738.SGD","LU2756315318.SGD","VHT","LU2491050071.SGD","LU0786609619.USD","LU2462591350.SGD","LU0417516902.SGD","LU0823434583.USD","BK4007","LU0006306889.USD","LU0079474960.USD","LU2211815571.USD","LU0326950275.SGD","FTXH","LU0964807845.USD","LU1623119135.USD","IE00B775H168.HKD","SG9999015945.SGD","LU0516423091.SGD","SG9999018857.SGD","LU1069344957.HKD","LU0122379950.USD","LU0320764599.SGD","LU1969619763.USD","WDNA","IE00BKDWB100.SGD","LU2271345857.HKD","LU1720051108.HKD","AGNG","BK0187","LU0052750758.USD","LU0708994859.HKD","SKHU","IE0009355771.USD","LU2237443382.USD","ELIS","LU0359201612.USD","LU0640476718.USD","IE00B4R5TH58.HKD","LU1267930730.SGD","LU1688375341.USD","LU0882574139.USD","LU2168563687.JPY","LU2265009873.SGD","LU0354030511.USD","LU1232071149.USD","LU0106261372.USD","LU0039217434.USD","LU1551013425.SGD","THNR","LU2456880835.USD","LU0289739699.SGD","IE00BWXC8680.SGD","SG9999014898.SGD","MHIP","LU1064131342.USD","LU0029874061.USD","LU0353189763.USD","IE00B2B36J28.USD","LU1280957306.USD","BK4534","KURE","LU0456827905.SGD","AZNH","PPH","LU0307460666.USD","LU0823426480.USD","LU0238689110.USD","LU2896262040.SGD","LU2471134796.USD","LU2089284900.SGD","IE00B0JY6N72.USD","LU0058720904.USD","LU1242518857.USD","LU0889565916.HKD","SKHZ","IE00B1XK9C88.USD","IE0005OL40V9.USD","HRTS","BK4533","LU2746668461.USD","LU1035775433.USD","LU2264538146.SGD","LU0359202008.SGD","LU0234572021.USD","LU0158827781.USD","SGXZ99366536.SGD","LU0417517546.SGD","LU2417539215.USD","LU0198837287.USD","LU0348735423.USD","LU1023059063.AUD","LU0203201768.USD","LU0820561818.USD","LU2089283258.USD","LU1868837136.USD","SG9999002562.SGD","LU2237443549.SGD","LU2491050154.USD","LU1917777945.USD","LU1242518931.SGD","LU1366192091.USD","IE0001KFT4U8.USD","LU2106854487.HKD","LU1061106388.HKD","LU0345770308.USD","LU0210536198.USD","002493","LU0327786744.USD","LU1868836914.USD","XLV","LU1291159041.SGD","LU2168564065.EUR","LU1868837300.USD","LU2468319806.SGD","LU2462157665.USD","HYNX","ABB","BK0197","LU2461242641.AUD","LU1629891620.HKD","LU2168564149.EUR","MEDX","LU2361044949.HKD","LU2750360997.AUD","IE00BJLML261.HKD","LU2328871848.SGD","LU0471298694.HKD","LU2746668974.SGD","LU0672654240.SGD","LU2552382215.SGD","WXXWY","CANC","LU0823426308.USD","LU1548497426.USD","LU0943347566.SGD","LU1868836757.USD","IE00BJJMRY28.SGD","LU0787776722.HKD","LU0029864427.USD","LU0266013472.USD","LU2108987350.USD","LU0203202063.USD","MEDI","LU0456846285.SGD","ELIL","LLYZ","LU2750360641.GBP","SGXZ57979304.SGD","SKHL","LU0109394709.USD","LU1829250122.USD","IE00BK4W5L77.USD","FHLC","LU0320765992.SGD","LU2237443978.SGD","BK4581","LU1093756325.SGD","SG9999018865.SGD","LU0158827948.USD","LU2237443895.HKD","LU0348825331.USD","SKHN","BK1521","SKDD","LU0516423174.USD","LU0456855351.SGD","LU2111349929.HKD","BK1141","LU0708995401.HKD","LU0819121731.USD","LU0820562030.AUD","JDOC","LU0345770993.USD","LU0708995583.HKD","LU2602419157.SGD","LU1267930573.SGD","LU2471134523.USD","BK1589","LU0256863902.USD","LU0323591593.USD","LU2324357040.USD","GB00BDT5M118.USD","07709","LU0820561909.HKD","RXL","LU0353189680.USD","SGXZ31699556.SGD","IE0004445239.USD","LU1880383366.USD","BK4599","SG9999002463.SGD","LU0823434740.USD","LU0471298777.SGD","LU0043850808.USD","LU2471134879.HKD","SGXZ81514606.USD","LU2023251221.USD","LU2491049909.HKD","BK4588","LU0109391861.USD","SKHQ","LU0823416689.USD","LLYX","IE0004445015.USD","LU0466842654.USD","SG9999015986.USD","SKHYV","LU1712237335.SGD","LU1988902786.USD","LU1974910355.USD","IE00BJT1NW94.SGD","LU1145028129.USD","SG9999015952.SGD","LU1127390331.HKD","SG9999001176.USD","IYH","LU2357305700.SGD","AZN","LU0051755006.USD","LU1551013342.USD","TMED","SG9999017495.SGD","IXJ","LU2089984988.USD","LU0225283273.USD","LU0354030438.USD","IE00BJJMRX11.SGD","IE00BFSS8Q28.SGD","LU2361045086.USD","LU1868836591.USD","BK4516","LU2236285917.USD","SG9999013999.USD","IE00B1BXHZ80.USD","IE0002141913.USD","IE00BKPKM429.USD","LU0979878070.USD","LU1979441026.SGD","BK0208","LU2087625088.SGD","IE00B7KXQ091.USD","LU1794554557.SGD","CURE","IE00B3T34201.USD","LU1720050803.USD","OZEM","LU1814569148.SGD","LU0096364046.USD","BK0028","LU2028103732.USD","LU0516422952.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106512590","title":"药明生物自5月27日至7月7日回购3,982.45万股，涉资约12.72亿港元，并于9月7日发行180.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1106512590","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106512590?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:57","pubTimestamp":1788785863,"startTime":"0","endTime":"0","summary":"9月7日，药明生物发布翌日披露报表。公告显示，公司自2026年5月27日至2026年7月7日期间，累计回购39,824,500股，占当时已发行股本相应百分比区间介乎0.03488%至0.15741%，回购价格介乎每股29.46港元至36.75港元，累计涉及总金额约12.72亿港元。上述回购股份尚未注销。本次发行完成后，公司于2026年9月7日的已发行股本增至4,154,733,877股。公司在公告中确认，已严格遵守香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物自5月27日至7月7日回购3,982.45万股，涉资约12.72亿港元，并于9月7日发行180.41万股","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184934047","title":"药明生物9月4日增发320万股并累计回购3982.45万股，耗资约12.72亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184934047","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184934047?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:02","pubTimestamp":1788523362,"startTime":"0","endTime":"0","summary":"药明生物于2026年9月4日发布翌日披露报表。公告显示，公司于当日根据2016年1月5日采纳的首次公开发售前购股权计划，因董事行使期权，发行了普通股320万股，每股发行价为2.64港元，合计约0.08亿港元，占发行前现有已发行股份约0.07711%。本次增发后，公司已发行股份总数由4,149,729,787股增至4,152,929,787股。此外，公司自2026年5月27日至2026年7月7日期间累计回购了39,824,500股，约占截至回购首日前公司已发行股本的0.96%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物9月4日增发320万股并累计回购3982.45万股，耗资约12.72亿港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.0547},{"period":"1month","weight":0.0313},{"period":"3month","weight":0.6256},{"period":"6month","weight":0.4814},{"period":"1year","weight":0.2774},{"period":"ytd","weight":0.5935}],"compareEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":-0.034},{"period":"3month","weight":0.0284},{"period":"6month","weight":-0.0266},{"period":"1year","weight":-0.0856},{"period":"ytd","weight":-0.04}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.085288},{"month":8,"riseRate":0.6,"avgChangeRate":0.053299},{"month":9,"riseRate":0.7,"avgChangeRate":0.053283},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}